抗癌剤ゲフィチニブによる副作用発症機構の解明及び新規抗腫瘍作用の探索

1.

Herbst, R. S. Review of epidermal growth factor receptor biology. Int. J. Radiat. Oncol. Biol.

Phys. 59, S21–S26 (2004).

2.

Saraon, P. et al. Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic

approaches. Oncogene 40, 4079–4093 (2021).

3.

Araki, T. et al. Review of the treatment of non-small cell lung cancer with gefitinib. Clin. Med.

Insights Oncol. 6, 407–421 (2012).

4.

Inoue, A. et al. Severe acute interstitial pneumonia and gefitinib. Lancet 361, 137–139 (2003).

5.

Strieter, R. M. & Keane, M. P. Innate immunity dictates cytokine polarization relevant to the

development of pulmonary fibrosis. 165–168 (2004) doi:10.1172/JCI200420964.8.

6.

Schroder, K. & Tschopp, J. The Inflammasomes. Cell 140, 821–832 (2010).

7.

Rodrigues, T. S. et al. Inflammasomes are activated in response to SARS-cov-2 infection and

are associated with COVID-19 severity in patients. J. Exp. Med. 218, (2020).

8.

Duewell, P. et al. NLRP3 inflammasomes are required for atherogenesis and activated by

cholesterol crystals. Nature 464, 1357–1361 (2010).

9.

Halle, A. et al. The NALP3 inflammasome is involved in the innate immune response to

amyloid-β. Nat. Immunol. 9, 857–865 (2008).

10.

Kagi, T. et al. The polypeptide antibiotic polymyxin B acts as a pro-inflammatory irritant by

preferentially targeting macrophages. J. Antibiot. (Tokyo). 75, 29–39 (2022).

11.

Allam, R. et al. Cutting Edge: Cyclic Polypeptide and Aminoglycoside Antibiotics Trigger IL1β Secretion by Activating the NLRP3 Inflammasome. J. Immunol. 186, 2714–2718 (2011).

12.

Heneka, M. T. et al. NLRP3 is activated in Alzheimer’s disease and contributes to pathology in

APP/PS1 mice. Nature 493, 674–678 (2013).

93

13.

Van Der Heijden, T. et al. NLRP3 Inflammasome Inhibition by MCC950 Reduces

Atherosclerotic Lesion Development in Apolipoprotein E-Deficient Mice - Brief Report.

Arterioscler. Thromb. Vasc. Biol. 37, 1457–1461 (2017).

14.

Mulay, S. R. et al. Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL1β secretion. J. Clin. Invest. 123, 236–246 (2013).

15.

Mridha, A. R. et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in

experimental NASH in mice. J. Hepatol. 66, 1037–1046 (2017).

16.

Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid

crystals activate the NALP3 inflammasome. Nature 440, 237–241 (2006).

17.

Masters, S. L. et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide

provides a mechanism for enhanced IL-1β 2 in type 2 diabetes. Nat. Immunol. 11, 897–904

(2010).

18.

Mangan, M. S. J. et al. Targeting the NLRP3 inflammasome in inflammatory diseases. Nat. Rev.

Drug Discov. 17, 588–606 (2018).

19.

Zhou, R., Yazdi, A. S., Menu, P. & Tschopp, J. A role for mitochondria in NLRP3

inflammasome activation. Nature 469, 221–226 (2011).

20.

Zhong, Z. et al. New mitochondrial DNA synthesis enables NLRP3 inflammasome activation.

Nature 560, 198–203 (2018).

21.

Xian, H. et al. Oxidized DNA fragments exit mitochondria via mPTP- and VDAC-dependent

channels to activate NLRP3 inflammasome and interferon signaling. Immunity 55, 13701385.e8 (2022).

22.

Martin, G. S. The road to Src. Oncogene 23, 7910–7917 (2004).

23.

Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase

complement of the human genome. Science (80-. ). 298, 1912–1934 (2002).

94

24.

Salvi, M. et al. Characterization and location of Src-dependent tyrosine phosphorylation in rat

brain mitochondria. Biochim. Biophys. Acta - Mol. Cell Res. 1589, 181–195 (2002).

25.

Miyazaki, T., Neff, L., Tanaka, S., Horne, W. C. & Baron, R. Regulation of cytochrome c

oxidase activity by c-Src in osteoclasts. J. Cell Biol. 160, 709–718 (2003).

26.

Salvi, M., Morrice, N. A., Brunati, A. M. & Toninello, A. Identification of the flavoprotein of

succinate dehydrogenase and aconitase as in vitro mitochondrial substrates of Fgr tyrosine

kinase. FEBS Lett. 581, 5579–5585 (2007).

27.

Hebert-Chatelain, E. Src kinases are important regulators of mitochondrial functions. Int. J.

Biochem. Cell Biol. 45, 90–98 (2013).

28.

Acín-Pérez, R. et al. ROS-triggered phosphorylation of complex II by Fgr kinase regulates

cellular adaptation to fuel use. Cell Metab. 19, 1020–1033 (2014).

29.

Matsushima, S. et al. Tyrosine kinase FYN negatively regulates NOX4 in cardiac remodeling. J.

Clin. Invest. 126, 3403–3416 (2016).

30.

Shien, T. et al. PLC and PI3K pathways are important in the inhibition of EGF-induced cell

migration by gefitinib (‘Iressa’, ZD1839). Breast Cancer 11, 367–373 (2004).

31.

Karaman, M. W. et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol.

26, 127–132 (2008).

32.

Brehmer, D. et al. Cellular targets of gefitinib. Cancer Res. 65, 379–382 (2005).

33.

Peter, M. E. & Krammer, P. H. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 10,

26–35 (2003).

34.

Guicciardi, M. E. & Gores, G. J. Life and death by death receptors. FASEB J. 23, 1625–1637

(2009).

35.

O’Connell, J., GC, O., JK, C. & Shanahan, F. The Fas counterattack: Fas-mediated T cell killing

by colon cancer cells expressing Fas ligand. J. Exp. Med. 184, 1075 (1996).

95

36.

Ajayi, I. O. et al. X-linked inhibitor of apoptosis regulates lung fibroblast resistance to fasmediated apoptosis. Am. J. Respir. Cell Mol. Biol. 49, 86–95 (2013).

37.

Bennett, M. et al. Cell surface trafficking of Fas: A rapid mechanism of p53-mediated

apoptosis. Science (80-. ). 282, 290–293 (1998).

38.

Guan, X. Cancer metastases: Challenges and opportunities. Acta Pharm. Sin. B 5, 402–418

(2015).

39.

Yamaguchi, H. & Condeelis, J. Regulation of the actin cytoskeleton in cancer cell migration and

invasion. Biochim. Biophys. Acta - Mol. Cell Res. 1773, 642–652 (2007).

40.

Sahai, E. Mechanisms of cancer cell invasion. Curr. Opin. Genet. Dev. 15, 87–96 (2005).

41.

Katsuragi, Y., Ichimura, Y. & Komatsu, M. P62/SQSTM1 functions as a signaling hub and an

autophagy adaptor. FEBS J. 282, 4672–4678 (2015).

42.

Sánchez-Martın, P. & Komatsu, M. p62/SQSTM1 – Steering the cell through health and disease.

J. Cell Sci. 131, (2018).

43.

Salminen, A. et al. Emerging role of p62/sequestosome-1 in the pathogenesis of Alzheimer’s

disease. Prog. Neurobiol. 96, 87–95 (2012).

44.

Liang, X. & Guan, X. p62/SQSTM1: A potential molecular target for treatment of

atherosclerosis. Front. Lab. Med. 1, 104–106 (2017).

45.

Moscat, J., Karin, M. & Diaz-Meco, M. T. p62 in Cancer: Signaling Adaptor Beyond

Autophagy. Cell 167, 606–609 (2016).

46.

Noguchi, T. et al. Nuclear-accumulated SQSTM1/p62-based ALIS act as microdomains sensing

cellular stresses and triggering oxidative stress-induced parthanatos. Cell Death Dis. 9, (2018).

47.

Johansen, T. & Lamark, T. Selective autophagy mediated by autophagic adapter proteins.

Autophagy 7, 279–296 (2011).

48.

Kirkin, V., Lamark, T., Johansen, T. & Dikic, I. NBR1 cooperates with p62 in selective

autophagy of ubiquitinated targets. Autophagy 5, 732–733 (2009).

96

49.

Komatsu, M. & Ichimura, Y. Physiological significance of selective degradation of p62 by

autophagy. FEBS Lett. 584, 1374–1378 (2010).

50.

Hyman, A. A., Weber, C. A. & Jülicher, F. Liquid-liquid phase separation in biology. Annu.

Rev. Cell Dev. Biol. 30, 39–58 (2014).

51.

Shin, Y. & Brangwynne, C. P. Liquid phase condensation in cell physiology and disease.

Science (80-. ). 357, (2017).

52.

Sun, D., Wu, R., Zheng, J., Li, P. & Yu, L. Polyubiquitin chain-induced p62 phase separation

drives autophagic cargo segregation. Cell Res. 28, 405–415 (2018).

53.

Kageyama, S. et al. p62/SQSTM1-droplet serves as a platform for autophagosome formation

and anti-oxidative stress response. Nat. Commun. 12, (2021).

54.

Kenneth, N. S. & Duckett, C. S. IAP proteins: Regulators of cell migration and development.

Curr. Opin. Cell Biol. 24, 871–875 (2012).

55.

Oberoi, T. K. et al. IAPs regulate the plasticity of cell migration by directly targeting Rac1 for

degradation. EMBO J. 31, 14–28 (2012).

56.

Dueber, E. C. Antagonists Induce a Conformational. 376, (2011).

57.

El-Mesery, M., Shaker, M. E. & Elgaml, A. The SMAC mimetic BV6 induces cell death and

sensitizes different cell lines to TNF-α and TRAIL-induced apoptosis. Exp. Biol. Med. 241,

2015–2022 (2016).

58.

Varfolomeev, E. et al. IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB

Activation, and TNFα-Dependent Apoptosis. Cell 131, 669–681 (2007).

59.

Bid, H. K., Roberts, R. D., Manchanda, P. K. & Houghton, P. J. RAC1: An emerging

therapeutic option for targeting cancer angiogenesis and metastasis. Mol. Cancer Ther. 12,

1925–1934 (2013).

60.

Mana, G., Valdembri, D. & Serini, G. Conformationally active integrin endocytosis and traffic:

Why, where, when and how? Biochem. Soc. Trans. 48, 83–93 (2020).

97

61.

Marei, H. & Malliri, A. Rac1 in human diseases: The therapeutic potential of targeting Rac1

signaling regulatory mechanisms. Small GTPases 8, 139–163 (2017).

62.

Krauthammer, M. et al. Exome sequencing identifies recurrent somatic RAC1 mutations in

melanoma. Nat. Genet. 44, 1006–1014 (2012).

63.

Hwang, S. L. et al. Rac1 gene mutations in human brain tumours. Eur. J. Surg. Oncol. 30, 68–

72 (2004).

64.

Hodis, E. et al. A landscape of driver mutations in melanoma. Cell 150, 251–263 (2012).

65.

Gómez Del Pulgar, T., Benitah, S. A., Valerón, P. F., Espina, C. & Lacal, J. C. Rho GTPase

expression in tumourigenesis: Evidence for a significant link. BioEssays 27, 602–613 (2005).

66.

Li, T. et al. The ubiquitin E3 ligase TRAF6 exacerbates ischemic stroke by ubiquitinating and

activating rac1. J. Neurosci. 37, 12123–12140 (2017).

67.

Ballabio, A. & Bonifacino, J. S. Lysosomes as dynamic regulators of cell and organismal

homeostasis. Nat. Rev. Mol. Cell Biol. 21, 101–118 (2020).

68.

Lakpa, K. L. et al. and Pathological Relevance. 16, 219–237 (2021).

69.

Shantanam, S. & MUELLER. 乳鼠心肌提取 HHS Public Access. Physiol. Behav. 176, 139–

148 (2018).

70.

Martina, J. A. et al. The nutrient-responsive transcription factor TFE3 promotes autophagy,

lysosomal biogenesis, and clearance of cellular debris. Sci. Signal. 7, 1–16 (2014).

71.

Trouet, A. Lysosomotropic agents. Arch. Biol. (Liege). 86, 492–493 (1975).

72.

Nujić, K., Banjanac, M., Munić, V., Polančec, D. & Eraković Haber, V. Impairment of

lysosomal functions by azithromycin and chloroquine contributes to anti-inflammatory

phenotype. Cell. Immunol. 279, 78–86 (2012).

73.

Yoshimori, T., Yamamoto, A., Moriyama, Y., Futai, M. & Tashiro, Y. Bafilomycin A1, a

specific inhibitor of vacuolar-type H+-ATPase, inhibits acidification and protein degradation in

lysosomes of cultured cells. J. Biol. Chem. 266, 17707–17712 (1991).

98

74.

Yang, L. et al. EGFR TKIs impair lysosome-dependent degradation of SQSTM1 to compromise

the effectiveness in lung cancer. Signal Transduct. Target. Ther. 4, (2019).

75.

Coll, R. C. et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of

inflammatory diseases. Nat. Med. 21, 248–257 (2015).

76.

Smiley, S. T. et al. Intracellular heterogeneity in mitochondrial membrane potentials revealed

by a J-aggregate-forming lipophilic cation JC-1. Proc. Natl. Acad. Sci. U. S. A. 88, 3671–3675

(1991).

77.

Lim, S. et al. Regulation of mitochondrial functions by protein phosphorylation and

dephosphorylation. Cell Biosci. 6, 1–15 (2016).

78.

Huyer, G. et al. Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and

pervanadate. J. Biol. Chem. 272, 843–851 (1997).

79.

Ogura, M., Yamaki, J., Homma, M. K. & Homma, Y. Mitochondrial c-Src regulates cell

survival through phosphorylation of respiratory chain components. Biochem. J. 447, 281–289

(2012).

80.

Schreiner, S. J., Schiavone, A. P. & Smithgall, T. E. Activation of STAT3 by the Src Family

Kinase Hck Requires a Functional SH3 Domain * stimulation of DNA binding activity by five

members of. J. Biol. Chem. 277, 45680–45687 (2002).

81.

Yu, C. L. et al. Enhanced DNA-binding activity of a stat3-related protein in cells transformed

by the Src oncoprotein. Science (80-. ). 269, 81–83 (1995).

82.

Jin, K. R. et al. p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of

Fas in non-small cell lung cancer. Cancer Res. 67, 1163–1169 (2007).

83.

Chang, G. C. et al. An epidermal growth factor inhibitor, Gefitinib, induces apoptosis through a

p53-dependent upregulation of pro-apoptotic molecules and downregulation of anti-apoptotic

molecules in human lung adenocarcinoma A549 cells. Eur. J. Pharmacol. 600, 37–44 (2008).

99

84.

Lee, J. Y. et al. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates

p38 activation in intestine: The versatile adjuvant for gefitinib therapy. PLoS One 6, (2011).

85.

Okon, I. S., Coughlan, K. A., Zhang, M., Wang, Q. & Zou, M. H. Gefitinib-mediated reactive

oxygen specie (ROS) instigates mitochondrial dysfunction and drug resistance in lung cancer

cells. J. Biol. Chem. 290, 9101–9110 (2015).

86.

Moscat, J. & Diaz-Meco, M. T. p62 at the Crossroads of Autophagy, Apoptosis, and Cancer.

Cell 137, 1001–1004 (2009).

87.

Kirkin, V. et al. A Role for NBR1 in Autophagosomal Degradation of Ubiquitinated Substrates.

Mol. Cell 33, 505–516 (2009).

88.

Gal, J., Ström, A. L., Kilty, R., Zhang, F. & Zhu, H. P62 Accumulates and Enhances Aggregate

Formation in Model Systems of Familial Amyotrophic Lateral Sclerosis. J. Biol. Chem. 282,

11068–11077 (2007).

89.

Nicot, A. S. et al. Phosphorylation of NBR1 by GSK3 modulates protein aggregation.

Autophagy 10, 1036–1053 (2014).

90.

Kroschwald, S., Maharana, S. & Simon, A. Hexanediol: a chemical probe to investigate the

material properties of membrane-less compartments. Matters 1–7 (2017)

doi:10.19185/matters.201702000010.

91.

Itoh, Y. et al. 1,6-Hexanediol Rapidly Immobilizes and Condenses Chromatin in Living Human

Cells. Life Sci. Alliance 4, 1–13 (2021).

92.

Nadanaciva, S. et al. A high content screening assay for identifying lysosomotropic compounds.

Toxicol. Vitr. 25, 715–723 (2011).

93.

Bjørkøy, G. et al. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a

protective effect on huntingtin-induced cell death. J. Cell Biol. 171, 603–614 (2005).

94.

Grice, G. L. & Nathan, J. A. The recognition of ubiquitinated proteins by the proteasome. Cell.

Mol. Life Sci. 73, 3497–3506 (2016).

100

95.

McKillop, D. et al. Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor

tyrosine kinase inhibitor. Mol. Cancer Ther. 4, 641–649 (2005).

96.

Han, S. Y., Zhao, H. Y., Zhou, N., Zhou, F. & Li, P. P. Marsdenia tenacissima extract inhibits

gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6

enzymes. J. Ethnopharmacol. 151, 210–217 (2014).

97.

Kudoh, S. et al. Interstitial lung disease in Japanese patients with lung cancer: A cohort and

nested case-control study. Am. J. Respir. Crit. Care Med. 177, 1348–1357 (2008).

98.

Hara, H. et al. Mitochondrial fragmentation in cigarette smoke-induced bronchial epithelial cell

senescence. Am. J. Physiol. - Lung Cell. Mol. Physiol. 305, (2013).

99.

Van Der Toorn, M. et al. Cigarette smoke-induced blockade of the mitochondrial respiratory

chain switches lung epithelial cell apoptosis into necrosis. Am. J. Physiol. - Lung Cell. Mol.

Physiol. 292, 1211–1218 (2007).

100.

Swanson, K. V., Deng, M. & Ting, J. P. Y. The NLRP3 inflammasome: molecular activation

and regulation to therapeutics. Nat. Rev. Immunol. 19, 477–489 (2019).

101.

Bauernfeind, F. G. et al. Cutting Edge: NF-κB Activating Pattern Recognition and Cytokine

Receptors License NLRP3 Inflammasome Activation by Regulating NLRP3 Expression. J.

Immunol. 183, 787–791 (2009).

102.

Martinon, F., Burns, K. & Tschopp, J. The Inflammasome: A molecular platform triggering

activation of inflammatory caspases and processing of proIL-β. Mol. Cell 10, 417–426 (2002).

103.

Billingham, L. K. et al. Mitochondrial electron transport chain is necessary for NLRP3

inflammasome activation. Nature Immunology vol. 23 (Springer US, 2022).

104.

Guedouari, H., Ould Amer, Y., Pichaud, N. & Hebert-Chatelain, E. Characterization of the

interactome of c-Src within the mitochondrial matrix by proximity-dependent biotin

identification. Mitochondrion 57, 257–269 (2021).

101

105.

Ingley, E. Src family kinases: Regulation of their activities, levels and identification of new

pathways. Biochim. Biophys. Acta - Proteins Proteomics 1784, 56–65 (2008).

106.

Fão, L. et al. Restoration of c-Src/Fyn Proteins Rescues Mitochondrial Dysfunction in

Huntington’s Disease. Antioxid. Redox Signal. 00, 1–20 (2022).

107.

Siew, J. J. et al. Galectin-3 is required for the microglia-mediated brain inflammation in a model

of Huntington’s disease. Nat. Commun. 10, 1–18 (2019).

108.

Paldino, E. & Fusco, F. R. Emerging Role of NLRP3 Inflammasome / Pyroptosis in

Huntington ’ s Disease. (2022).

109.

Yang, J. W., Yang, L., Luo, R. G. & Xu, J. F. Corticosteroid administration for viral pneumonia:

COVID-19 and beyond. Clin. Microbiol. Infect. 26, 1171–1177 (2020).

110.

Rossin, A. et al. Fas palmitoylation by the palmitoyl acyltransferase DHHC7 regulates Fas

stability. Cell Death Differ. 22, 643–653 (2015).

111.

Davies, B. A., Lee, J. R. E., Oestreich, A. J. & Katzmann, D. J. Membrane protein targeting to

the MVB/lysosome. Chem. Rev. 109, 1575–1586 (2009).

112.

Huyghe, J. et al. ATG9A prevents TNF cytotoxicity by an unconventional lysosomal targeting

pathway. Science 378, 1201–1207 (2022).

113.

Mahmood, Z. & Shukla, Y. Death receptors: Targets for cancer therapy. Exp. Cell Res. 316,

887–899 (2010).

114.

Mali, P. et al. RNA-guided human genome engineering via Cas9. Science (80-. ). 339, 823–826

(2013).

115.

Naito, Y., Hino, K., Bono, H. & Ui-Tei, K. CRISPRdirect: Software for designing CRISPR/Cas

guide RNA with reduced off-target sites. Bioinformatics 31, 1120–1123 (2015).

102

発表論文リスト

(原著論文)

1.

“The anti-cancer drug gefitinib accelerates Fas-mediated apoptosis by enhancing caspase-8

activation in cancer cells”

Yuto Sekiguchi*, Mayuka Yamada*, Takuya Noguchi*, Chise Noomote, Mei Tsuchida, Yuki

Kudoh, Yusuke Hirata, Atsushi Matsuzawa.

*These authors contributed equally to this work.

The Journal of Toxicological Sciences, 44(6) 435-440, 2019.

2.

“Gefitinib initiates sterile inflammation by promoting IL-1β and HMGB1 release via two

distinct mechanisms”

Takuya Noguchi*, Yuto Sekiguchi*, Yuki Kudoh*, Rio Naganuma, Tomohiro Kagi, Akiko

Nishidate, Kazuhiro Maeda, Chizuru Ishii, Takashi Toyama, Yusuke Hirata, Gi-Wook Hwang,

and Atsushi Matsuzawa.

*These authors contributed equally to this work.

Cell Death and Disease, 12, 49, 2021.

(参考論文)

1.

“The NLRP3 inflammasome works as a sensor for detecting hypoactivity of the mitochondrial

Src family kinases”

Yuto Sekiguchi*, Saya Takano*, Takuya Noguchi*, Tomohiro Kagi, Ryuto Komatsu, Maoko

Tan, Yusuke Hirata, and Atsushi Matsuzawa.

*These authors contributed equally to this work.

The Journal of Immunology, in press.

103

謝辞

本研究を進めるにあたり、終始御指導御鞭撻を賜りました東北大学大学院薬学研究科衛

生化学分野 教授 松沢 厚 先生に厚く御礼申し上げます。

本論文をまとめるにあたり、有益なご助言を頂きました東北大学大学院薬学研究科生命

機能解析学分野 教授 倉田 祥一朗 先生に深く感謝いたします。

本論文をまとめるにあたり、有益なご助言を頂きました東北大学大学院薬学研究科分子

細胞生化学分野 教授 井上 飛鳥 先生に深く感謝いたします。

本研究を進めるにあたり、終始御指導御助言を頂きました東北大学院薬学研究科衛生化

学分野 准教授 野口 拓也 先生に深く感謝いたします。

本研究を進めるにあたり、御指導御助言を頂きました東北大学院薬学研究科衛生化学分

野 助教 平田 祐介 先生に深く感謝いたします。

本研究を進めるにあたり、研究機器の使用を快諾して頂きました東北大学大学院薬学研

究科分子細胞生化学分野ならびに代謝制御薬学分野の先生方に深く感謝いたします。

本研究を進めるにあたり、多大な御助言と御協力を頂きました東北大学大学院薬学研究

科衛生化学分野 高野 紗彩 氏に深く感謝いたします。

また、本研究を進めるにあたり多くの御助言と御協力を頂きました 鈴木 碧 氏、山田 真

佑花 氏、山田 侑杜 氏、島田 竜耶 氏、横沢 拓海 氏、鍵 智裕 氏、蘆田 諒 氏、江崎 雄

亮 氏、黒川 礼温 氏、小松 寛武 氏、濱野 修平 氏、伊藤 環 氏、鈴木 若奈 氏、矢吹 洋

佑 氏、山田 裕太郎 氏、伊東 諒 氏、大久保 拓海 氏、柏原 直樹 氏、小松 龍斗 氏、丹

真桜子 氏、大谷 航平 氏、小島 諒太 氏、田口 蒼真 氏、丸山 朋笑 氏、本間 希望 氏を

はじめとする東北大学大学院薬学研究科衛生化学分野の皆様及び卒業生の皆様に深く感謝

申し上げます。

104

...